Gyre Therapeutics Cash Flow Statement
NASDAQ: GYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.04+0.28 (+4.14%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gyre Therapeutics free cash flow
In fiscal 2025, Gyre Therapeutics generated $1.0 million of operating cash flow and spent $1.2 million on capital expenditures. That left free cash flow of -$180,000, a free-cash-flow margin of -0.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Gyre Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 9.88M | 17.90M | -85.48M | 4.31M | -87.93M | -56.24M | -55.18M | -30.05M | -21.56M | -16.95M |
| Net Income growth (YoY) | -44.80% | — | -2081.46% | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.48M | 1.55M | 1.07M | 1.09M | 290.00K | 138.00K | 146.00K | 149.00K | 173.00K | 389.00K |
| Stock-Based Compensation | 7.16M | 831.00K | 7.28M | 13.37M | 3.40M | 3.63M | 3.20M | 2.61M | 863.00K | 635.00K |
| Change in Working Capital | -14.63M | -7.12M | 2.14M | -525.00K | 442.00K | -2.64M | 8.14M | -1.55M | 735.00K | 855.00K |
| Operating Cash Flow | 1.01M | -3.64M | 25.89M | 10.68M | -83.75M | -55.05M | -43.61M | -28.55M | -19.94M | -18.47M |
| Capital Expenditures | -1.19M | -2.31M | -8.52M | -4.99M | -839.00K | — | -64.00K | -376.00K | -23.00K | -468.00K |
| Investing Cash Flow | -474.00K | -19.88M | -19.76M | -13.81M | 48.19M | 9.66M | 27.39M | -71.32M | -11.20M | -1.31M |
| Dividends Paid | — | — | — | -45.03M | — | — | — | — | — | — |
| Financing Cash Flow | 24.38M | 2.10M | 2.50M | -45.01M | 49.55M | 60.38M | 327.00K | 111.33M | 21.08M | 948.00K |
| Net Change in Cash | 25.26M | -21.70M | 8.33M | -5.03M | 13.99M | 14.99M | -15.89M | 11.46M | -10.05M | -18.83M |
| Free Cash Flow | -180.00K | -5.96M | 17.38M | 5.69M | -84.59M | -55.05M | -43.68M | -28.93M | -19.96M | -18.94M |
This table shows 10 annual periods of Gyre Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GYRE's reporting calendar. What is a cash flow statement?